← All trials
NCT06081348
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2023
- Primary completion
- Apr 30, 2024
- Completion date
- Apr 30, 2024
- First posted
- Oct 13, 2023
- Last posted
- Oct 23, 2023
- Enrollment
- 130
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of TorontoLead sponsor
- University of CalgaryCollaborator
- Canadian Institutes of Health Research (CIHR)Collaborator
- Dalhousie UniversityCollaborator
- University of TorontoCollaborator
- McMaster UniversityCollaborator
- Ontario Brain InstituteCollaborator
- Queen's University, BelfastCollaborator
- St. Justine's HospitalCollaborator
- University of TorontoCollaborator
- Unity Health TorontoCollaborator
- University of AlbertaCollaborator
- University of TorontoCollaborator
- University of Western OntarioCollaborator
Drugs studied
Indications studied
- Autism Spectrum Disorder
- Phobia, Social
- Adolescent
- Agoraphobia
- Anxiety
- Anxiety Disorders
- Anxiety, Separation
- Attention Deficit Disorder with Hyperactivity
- Autistic Disorder
- Fragile X Syndrome
- Tourette Syndrome
- Mutation
- Pediatrics
- Tic Disorders
- Tuberous Sclerosis
- Attention Deficit and Disruptive Behavior Disorders
- 22q11 Deletion Syndrome
- Neurodevelopmental Disorders
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.